Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies
Top Cited Papers
- 1 November 2006
- journal article
- review article
- Published by Elsevier in Clinical Therapeutics
- Vol. 28 (11) , 1779-1802
- https://doi.org/10.1016/j.clinthera.2006.11.015
Abstract
No abstract availableKeywords
This publication has 78 references indexed in Scilit:
- Critical Evaluation of Current Treatments in Metastatic Colorectal CancerThe Oncologist, 2005
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Systemic Therapy for Colorectal CancerNew England Journal of Medicine, 2005
- Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitroAngiogenesis, 2004
- Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell CancerJournal of Clinical Oncology, 2004
- Non-Small Cell Lung Cancer and Antiangiogenic Therapy: What Can Be Expected of Bevacizumab?The Oncologist, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Angiogenic growth factors and hypertensionAngiogenesis, 2004
- Effect of the vascular endothelial growth factor receptor‐2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude miceInternational Journal of Cancer, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000